Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA approves new influenza vaccine production facility

This article was originally published in The Gold Sheet

Executive Summary

On May 6 FDA announced approval of a new influenza vaccine manufacturing facility in Swiftwater, Pa., for the production of the influenza H1N1 (swine flu) virus. The facility is owned and operated by Sanofi Pasteur, which is one of the nation's largest seasonal flu vaccine producers as well as one of the world's earliest developers of vaccines. Sanofi will use the new facility to manufacture Fluzone, an egg-based influenza vaccine. The company finished constructing the $150 million, 140,000 square foot plant in July 2007 and the facility is now operating. On another front, the vaccine giant just announced that it just started construction of a new vaccine production center in Neuville-sur-Saone, in southeastern France, for the tropical dengue virus

You may also be interested in...



Pfizer Eyes EU Pegfilgrastim Roll-Out By 1 April As US Launch Is Confirmed

Pfizer will aim to have its biosimilar Neulasta (pegfilgrastim) product, Nyvepria, on the market in both the EU and US by the end of the current quarter, a company spokesperson has informed Generics Bulletin, following a successful US launch.

Samsung Bioepis Opens New HQ To Drive Next-Generation Biosimilars

With a biosimilar Lucentis (ranibizumab) candidate recently filed and Soliris (eculizumab), Eylea (aflibercept) and Prolia (denosumab) candidates in Phase III development, Samsung Bioepis has moved into its new domestic headquarters to spearhead its journey to the next level.

COVID-19: EU Dexamethasone Taw Filing Pulled

The withdrawal of the marketing authorization application for Dexamethasone Taw as a treatment for COVID-19 patients was revealed today in the January meeting agenda of the European Medicines Agency’s human medicines committee, the CHMP.

UsernamePublicRestriction

Register

LL1135495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel